Photo via TIME

A New Pill Could Reduce the Risk of Having a Second Stroke

Read the original at TIME ↗
Cite

Park, A. (2026, November 12). A New Pill Could Reduce the Risk of Having a Second Stroke. TIME. https://time.com/article/2026/11/12/new-pill-could-reduce-risk-second-stroke/

Dated from the outlet's own feed. Check the original for its byline.

TIME · collected 2026-11-12 · by Alice Park

Quick Summary

The U.S. Food and Drug Administration approved Asundexian, sold as Sunharbo, on November 9 to reduce the risk of recurrent ischemic strokes. In a study, the drug, when paired with antiplatelet therapy, reduced the risk of additional strokes by 26% over a year compared to a placebo and antiplatelet therapy. Approximately 795,000 people in the U.S. experience a stroke annually, with nearly one in four being recurrent. Asundexian targets Factor XIa, a clotting factor, without significantly increasing bleeding risk, making it promising for stroke prevention in those who have had a prior ischemic stroke or transient ischemic attack.
Written by AI on 2026-11-15, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

On November 9, 2026, the U.S. Food and Drug Administration (FDA) approved a new daily pill called Sunharbo, which is the first medication to target a specific factor in the blood-clotting process linked to stroke risk. Developed by Bayer, the drug, when combined with an antiplatelet therapy like aspirin, reduced the risk of an additional stroke by 26% in just over a year compared to patients who received a placebo and antiplatelet therapy. Sunharbo is approved for individuals who have recently experienced an ischemic stroke or a transient ischemic attack. Dr. Ashkan Shoamanesh, a professor at McMaster University and co-leader of the trial, expressed enthusiasm about the drug's approval, noting that the positive feedback from the international stroke community is robust.

Written for “New Pill for Stroke Prevention” on 2026-11-18, grounded in this article and the 0 other(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Story

New Pill for Stroke Prevention
Health · 1 article(s) covering the same event.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
27
sentences that state something as happening or true
Uncertain
7%
2 of 27 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
60/100
TIME's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-15 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

TIME · 1023 article(s) · 2 correction(s) detected
Running correction rate · 2 correction(s)

Who wrote this

Alice Park
9 article(s) here · 1 carrying a prediction
A calculation that takes into account a person’s weight and height, BMI is supposed to reflect how much excess fat a person might be carrying and give doctors a sense of a patient's risk for obesity-related health conditions.
2026-11-13 · assertive framing · Why BMI Is Not the Best Measure of Health
Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke.
On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public.
2026-11-12 · assertive framing · The Next Chapter of mRNA
The results will be presented at the European Society of Medical Oncology meeting in Madrid on Oct. 24.
Immune-based treatments for cancer have become the biggest new advance in tackling tumors, and the latest approval could make a big difference for some people with rectal cancer.
The scientists used a modified version of a reprogramming strategy that earned a Nobel Prize in 2012 for turning mature, adult cells back to an embryonic-like state from which they could become any of the cells in the body—including healthy new versions of diseased or older cells.
Since each has specific receptors in the body and brain, targeting all three may be contributing to the more potent effects on weight for people with diabetes than drugs that target GLP-1 alone, like Ozempic and Wegovy (semaglutide), or GLP-1 and GIP together, as Mounjaro and Zepbound (tirzepatide) do.
In a new study published in Science, researchers report that for some of those cases, an inherited genetic mutation might be involved.
Also by Alice Park
The Next Chapter of mRNA
2026-11-12 · TIME
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 9 articles by Alice Park →

Topics

Asundexian Bayer FDA U.S. the U.S. Food and Drug Administration

Subjects

Shoamanesh PERSON · 5× Bayer ORG · 4× FDA ORG · 2× U.S. GPE · 2× Ashkan Shoamanesh PERSON · 1× Asundexian ORG · 1× Christoph Koenen PERSON · 1× Koenen PERSON · 1× McMaster University ORG · 1× the U.S. Food and Drug Administration ORG · 1×

Narrative

One of the findings that most impressed the researchers was that "it didn’t matter how old people were, from what part of the world, what their medical history was, or what type of ischemic stroke they had—all of the patients seem to benefit similarly from the treatment,” says Shoamanesh.
framing: assertive · carried by 1 article(s) · first seen 2026-11-15
Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke.
2026-11-15 · TIME
A New Pill Could Reduce the Risk of Having a Second Stroke · assertive framing

Claims (27 extracted, 2 hedged)

On November 9, the U.S. Food and Drug Administration (FDA) approved a new type of medication to reduce the risk of strokes in certain populations. asserted
Administration → approve → populations
Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke. asserted
that → sell → stroke
In a study submitted to the FDA by Bayer, researchers found that the drug, when combined with an antiplatelet therapy such as aspirin, reduced the risk of an additional stroke by 26% in just over a year compared to people who received placebo and the antiplatelet therapy. asserted
who → submit → placebo
The drug is approved for people who have recently had an ischemic stroke, which occur when clots block blood flow to the brain, or a transient ischemic attack caused by a temporary blockage of blood flow to the brain that doesn’t cause permanent damage. asserted
that → approve → damage
“The data is quite robust, and the feedback from the international stroke community is positive,” says Dr. Ashkan Shoamanesh, professor of medicine at McMaster University, who co-led the trial. asserted
who → say → trial
“We’re eager to have this on hand as soon as possible for patients. asserted
We → ’re → patients
There are two types of strokes: ischemic strokes, caused by blockages in the blood vessels, can impede blood flow to critical organs including the brain, and hemorrhagic strokes, caused by weakened blood vessels that burst in the brain and cause excessive bleeding. asserted
that → be → bleeding
Each year, about 795,000 people in the U.S. have a stroke, and nearly one in four strokes occur in people who have previously had one. asserted
who → have → one
Recurrent strokes represent an unmet treatment challenge, says Shoamanesh. asserted
Shoamanesh → represent → challenge
But treating ischemic strokes requires using just enough clot-breaking—or blood thinning—medications to dissolve the blockage without causing excessive bleeding. asserted
treating → treat → bleeding
Asundexian appears to do just that. asserted
Asundexian → appear → that
The 26% reduction in stroke risk occurred without any significant increase in bleeding events, according to Bayer’s data. uncertain
reduction → occur → data
“We used to always have a challenging balancing act,” says Shoamanesh. asserted
Shoamanesh → use → act
“Here we have the major benefits without the bleeding risk, so there is a large amount of excitement.” asserted
we → have → excitement
Researchers have known for years that some people born with a genetically driven lower risk of stroke have lower levels of a compound involved in blood clotting, called Factor XIa, in their blood. asserted
people → know → blood
It's a minor contributor to forming clots when the body experiences a major bleeding trauma like an injury, but it plays a bigger role in smaller vessel ruptures, some of which can contribute to stroke, asserted
some → form → stroke
says Shoamanesh. asserted
Shoamanesh → say → ?
It took more than a decade for scientists to turn that observation into a viable medication, says Dr. Christoph Koenen, chief medical officer at Bayer. asserted
Koenen → take → Bayer
But asundexian prevents small clots that may form in the vessels from becoming larger ones that can grow to block blood flow. uncertain
that → prevent → flow
One of the findings that most impressed the researchers was that "it didn’t matter how old people were, from what part of the world, what their medical history was, or what type of ischemic stroke they had—all of the patients seem to benefit similarly from the treatment,” says Shoamanesh. asserted
Shoamanesh → impress → treatment
Given the encouraging results in reducing the risk of recurrent strokes, Koenen says Bayer is exploring "if there are other benefits of asundexian we can bring to different patient populations. asserted
we → give → populations
Asundexian will be available starting in November. asserted
Asundexian → start → November
Shoamanesh expects that in order to truly benefit from the drug, patients will have to take the daily pills for the rest of their lives. asserted
patients → expect → lives
Data that tracked some of the study participants for several more years showed that those on the drug continued to show lower risk of stroke compared to those taking placebo. asserted
those → track → placebo
“That means that the drug continued to provide an advantage even at later time points,” he says. asserted
he → mean → points
“So we expect this to be a lifelong drug based on the data. asserted
this → expect → data
And we expect this will be the new standard of care.” asserted
this → expect → care
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support